Increased circulating obestatin in patients with chronic obstructive pulmonary disease

Area of Science:

• Metabolic regulation
• Chronic Obstructive Pulmonary Disease (COPD) research
• Inflammation markers

Background:

• Peptides regulating metabolic balance are implicated in COPD's nutritional disorders and inflammation.
• Obestatin administration in rats reduced body weight; it's also linked to rheumatoid arthritis inflammation.

Purpose of the Study:

• To measure circulating obestatin levels in COPD patients.
• To examine the relationship between obestatin, nutritional status, and systemic inflammation in COPD.

Main Methods:

• Assessed 32 underweight COPD patients (BMI < 20 kg/m²) and 22 controls.
• Measured body composition via BIA, circulating obestatin (ELISA), pulmonary function, TNF-α, and C-reactive protein.

Main Results:

• COPD patients had higher circulating obestatin (5562.75 ± 3435.43 pg/ml) than controls (3663.90 ± 2313.95 pg/ml; p=0.028).
• COPD patients showed lower BMI, waist/hip circumference, body fat percentage.
• Obestatin positively correlated with C-reactive protein and TNF-α, but not BMI or pulmonary function.

Conclusions:

• Circulating obestatin is elevated in underweight COPD patients.
• Obestatin levels correlate positively with systemic inflammation markers (CRP, TNF-α).
• Obestatin levels did not show a significant correlation with nutritional status (BMI) or pulmonary function in COPD.